VJHemOnc is committed to improving our service to you

EHA 2019 | Moving to the frontline: gilteritinib plus chemo for newly diagnosed AML

VJHemOnc is committed to improving our service to you

Alexander Perl

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, explains the updated results from the Phase I study (NCT02236013) of gilteritinib in combination with induction and consolidation therapy in newly diagnosed acute myeloid leukemia (AML). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter